Imatinib reduces bone marrow fibrosis and overwhelms the adverse prognostic impact of reticulin formation in patients with chronic myeloid leukaemia

Simsek, Eda; Eskazan, Ahmet; Cengiz, Mahir; AR, MUHLİS; Ekizoglu, Seda; Salihoglu, Ayse; Gulturk, Emine; ELVERDİ, TUĞRUL; Aydin, Seniz; DEMİRÖZ, AHU; Buyru, Ayse; Baslar, Zafer; ÖZBEK, UĞUR; Ferhanoglu, Burhan; Aydin, Yildiz; Tuzuner, Nukhet; Soysal, Teoman

doi:10.1136/jclinpath-2015-203320

Imatinib reduces bone marrow fibrosis and overwhelms the adverse prognostic impact of reticulin formation in patients with chronic myeloid leukaemia

Atıf İçin Kopyala

Simsek E. T., Eskazan A. E., Cengiz M., AR M. C., Ekizoglu S., Salihoglu A., ...Daha Fazla

JOURNAL OF CLINICAL PATHOLOGY, cilt.69, sa.9, ss.810-816, 2016 (SCI-Expanded)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 69 Sayı: 9
Basım Tarihi: 2016
Doi Numarası: 10.1136/jclinpath-2015-203320
Dergi Adı: JOURNAL OF CLINICAL PATHOLOGY
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.810-816
Anahtar Kelimeler: CML, MYELOFIBROS, HEMATOPATHOLOGY, CHRONIC MYELOGENOUS LEUKEMIA, KINASE INHIBITOR STI571, CHRONIC-PHASE, RELEVANCE, THERAPY, RECOMMENDATIONS, DIAGNOSIS
Acıbadem Mehmet Ali Aydınlar Üniversitesi Adresli: Hayır

Özet

Aims Before the era of tyrosine kinase inhibitors (TKIs), the presence of bone marrow fibrosis (MF) in patients with chronic myeloid leukaemia (CML) has been established as a poor prognostic factor. The aim of the present study was to evaluate the effects of imatinib treatment on MF and the prognostic significance of MF at this new era of CML therapy.